Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer

Core Insights - Akeso Inc. has initiated a registrational Phase II study (AK130-202) for its bifunctional antibody fusion protein AK130, in combination with ivonescimab, targeting locally advanced or metastatic pancreatic cancer patients who have failed up to two prior lines of systemic therapy [1][6]. Group 1: Product Development - AK130 is the first and only TIGIT/TGF- bifunctional antibody fusion protein in registrational clinical development globally, marking a significant milestone in Akeso's strategy of combining immuno-oncology therapies [2][6]. - The company has developed nine bispecific antibodies or bispecific antibody-drug conjugates (ADCs) that are either in clinical development or have received regulatory approval, showcasing its robust pipeline [3]. Group 2: Mechanism and Efficacy - Preclinical studies suggest that the dual blockade of PD-1/VEGF and TIGIT/TGF- pathways has synergistic therapeutic potential, which may enhance anti-tumor immune responses and remodel the tumor immune microenvironment [4]. - AK130 is designed to activate T-cell responses while reducing immunosuppressive activity, potentially leading to improved anti-tumor effects in challenging malignancies like pancreatic cancer [5]. Group 3: Company Overview - Founded in 2012, Akeso is a leading biopharmaceutical company focused on innovative biological medicines, with a comprehensive end-to-end drug development platform and a strong pipeline of over 50 innovative assets across various disease areas [10]. - The company aims to provide affordable therapeutic antibodies globally and create significant commercial and social value, positioning itself as a competitive player in the biopharmaceutical industry [10].